Single-cell extracellular vesicle-program scoring maps immunometabolic rewiring and immune crosstalk of mesenchymal stromal cells in intervertebral disc degeneration, prioritizing AP2S1 and CSTB - Top-Institutions - MDSpire

Single-cell extracellular vesicle-program scoring maps immunometabolic rewiring and immune crosstalk of mesenchymal stromal cells in intervertebral disc degeneration, prioritizing AP2S1 and CSTB

  • By

  • Fengyu Ma

  • Kelv Shen

  • Ziqiang Wu

  • Hanshi Yang

  • Mingzhe Yu

  • Zhendong Huang

  • Fengxuan Han

  • Zhengfeng Lu

  • May 22, 2026

  • 0 min

Share

Top Institutions in Orthopedic Medicine

Brief introduction explaining scope and methodology.

  • #1

    Hospital for Special Surgery
    Hospital for Special Surgery

    New York, NY

    Key Differentiators

    • Orthopedics
    • Spine Surgery

  • #2

    Mayo Clinic
    Mayo Clinic

    Rochester, MN

    Key Differentiators

    • Orthopedics
    • Regenerative Medicine

  • #3

    Cleveland Clinic
    Cleveland Clinic

    Cleveland, OH

    Key Differentiators

    • Orthopedics
    • Spine Surgery

  • #4

    NIH Clinical Center
    NIH Clinical Center

    Bethesda, MD

    Key Differentiators

    • Orthopedics
    • Clinical Research

  • #5

    PLA General Hospital
    PLA General Hospital

    Beijing, China

    Key Differentiators

    • Orthopedics
    • Clinical Research

Original Source(s)

Single-cell extracellular vesicle-program scoring maps immunometabolic rewiring and immune crosstalk of mesenchymal stromal cells in intervertebral disc degeneration, prioritizing AP2S1 and CSTB

  • by Fengyu Ma, Kelv Shen, Ziqiang Wu, Hanshi Yang, Mingzhe Yu, Zhendong Huang, Fengxuan Han, Zhengfeng Lu

  • May 22, 2026

Related Content

From algorithm to verification: based on network toxicology and machine learning, the immunomodulatory role of IGFBP1/MKI67/C9 in perfluorooctanoic acid-induced osteoarthritis was discovered, and a diagnostic model was constructed

Editorial: Pain management in spine surgery

RA Outcomes Improved in KURAMA Cohort

Ten-year observational data showed lower disease activity and functional disability coinciding with broader use of biologic and targeted synthetic therapies.